Formosa Pharmaceuticals is a is a clinical stage biopharmaceutical company with primary focus in the areas of ophthalmology and oncology.
News Highlight
- Harrow Acquires U.S. Commercial Rights to BYQLOVI (Clobetasol Propionate Ophthalmic Nanosuspension) 0.05% from Formosa Pharmaceuticals
- Formosa Pharmaceuticals and Adalvo Limited Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain
- Formosa Pharmaceuticals Announces Licensing Agreement with Apotex Inc., for Commercialization of Clobetasol Propionate Ophthalmic Suspension for Post-Ocular Surgery Inflammation and Pain for Mexico
Formosa Pharma is developing a unique pipeline consisting of risk-diverse development modes, including 505(b)(2), biosimilars, and NCEs. Our proprietary APNT® nanoparticle formulation platform, from which lead program APP13007 is derived, is available for application to drug candidates in need of improving pharmacokinetics and bioavailability.
